Novartis AG remains in the spotlight for several investment firms and analysts. The dividend guidance of this foreign pharmaceutical entity bagged positive acquires by entities such as
V Square Quantitative Management LLC,
Entropy Technologies LP, and
Mirae Asset Global Investments Co. Ltd., among others. However, rating adjustments from UBS and Morgan Stanley resulted in a downgrade. On the financial side, the Q4 earnings significantly surpassed the consensus, boosting
Novartis stocks by 5% post-announcement. Considering the growth forecast,
Novartis faces speculation of sharp deceleration by 2025, according to UBS. The
$3.1 billion deal acquisition of
Anthos Therapeutics serves as a significant move to enhance heart disease offerings. However, the market shows mixed responses, with concerns over disappointing Pluvicto results and stock downgrade. In contrast, the share performance is surprisingly high due to robust drug sales. Multiple firms, including
Kentucky Trust Co and
Foster Victor Wealth Advisors LLC, have acquired significant positions in
Novartis. However, the stock experienced sales from Arlington Partners LLC and Scharf Investments LLC. The company achieved an average target price of $123.38.
Novartis Stocks News Analytics from Thu, 18 Jul 2024 07:00:00 GMT to Sat, 15 Feb 2025 11:10:35 GMT -
Rating 3
- Innovation 0
- Information 6
- Rumor -6
